Product Details

Purity

≥ 95% as determined by SDS-PAGE.
≥ 95% as determined by SEC-HPLC.

Endotoxin

Less than 1.0 EU/ug as determined by LAL method.

Activity

①Measured by its binding ability in a functional ELISA.Immobilized Human TNFRSF10A at 2 μg/mL can bind anti-TNFRSF10A recombinant antibody(CSB-RA023964MA1HU).The EC50 is 1.038-1.260 ng/mL.
②TNFRSF10A Recombinant Monoclonal Antibody(CSB-RA023964MA1HU) captured on Protein A Chip can bind Human TNFRSF10A with an affinity constant of 0.851 nM as detected by MetaSPR Assay (WeSPRTM 200).

Target Names

TNFRSF10A

Uniprot No.

O00220

Alternative Names

Tumor necrosis factor receptor superfamily member 10A; Death receptor 4; TNF-related apoptosis-inducing ligand receptor 1; TRAIL receptor 1; TRAIL-R1; CD antigen CD261

Species

Homo sapiens (Human)

Source

Mammalian cell

Expression Region

24-239aa

Target Protein Sequence

ASGTEAAAATPSKVWGSSAGRIEPRGGGRGALPTSMGQHGPSARARAGRAPGPRPAREASPRLRVHKTFKFVVVGVLLQVVPSSAATIKLHDQSIGTQQWEHSPLGELCPPGSHRSEHPGACNRCTEGVGYTNASNNLFACLPCTACKSDEEERSPCTTTRNTACQCKPGTFRNDNSAEMCRKCSRGCPRGMVKVKDCTPWSDIECVHKESGNGHN

Mol. Weight

24.2 kDa

Protein Length

Partial

Tag Info

C-terminal 10xHis-tagged

Form

Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Buffer

Lyophilized from a 0.2 μm sterile filtered PBS, 6% Trehalose, pH 7.4

Reconstitution

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.

Troubleshooting and FAQs

Protein FAQs

Storage Condition

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.

Shelf Life

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.

Lead Time

3-7 business days

Notes

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Datasheet & COA

Please contact us to get it.

Description

Death receptor 4 mediates TRAIL-induced apoptosis in tumor cells, making it a critical target for cancer immunotherapy and antibody-based therapeutic development. This mammalian-expressed extracellular domain (aa 24–239) demonstrates sub-nanomolar binding affinity to a recombinant anti-TNFRSF10A antibody (KD = 0.851 nM by surface plasmon resonance), confirming native-like conformational integrity essential for therapeutic antibody epitope mapping and competitive inhibition screening. The protein supports quantitative ligand-binding assays with an EC50 of 1.038–1.260 ng/mL in functional ELISA, providing a validated basis for drug discovery campaigns targeting TRAIL receptor agonism or for screening blocking antibodies in cancer research. Purity exceeding 95% by both SDS-PAGE and SEC-HPLC, combined with endotoxin levels below 1.0 EU/μg, aligns with standards expected in surface plasmon resonance, biolayer interferometry, and antibody validation workflows where receptor quality directly impacts affinity measurements and epitope characterization.

Target Background

Function

Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B.

Gene References into Functions

A graphene-based nanocarrier modified with death receptor 4 (DR4) antibody and AKT siRNA has been developed, which can synergistically strengthen death receptor-mediated apoptosis and enhance the cancer therapeutic effect in vivo. PMID: 30430148
By downregulating TRAIL-R1, TGFbeta1 may not only promote tumor escape from immune surveillance but also negatively impact on TRAIL- or TRAIL-R1-based therapy regimens for treatment of Pancreatic ductal adenocarcinoma. PMID: 27492861
findings together highlight a previously undiscovered mechanism that positively regulates DR4 expression through activation of the MEK/ERK/AP-1 signaling pathway. PMID: 27576686
results suggest that the altered TRAIL, DR4 alleles and sTRAIL levels may be associated with some other potential biomarkers for vitiligo PMID: 26404509
These statistical data suggest that Thr209Arg in exon 4 of the TRAIL-R1 gene may not represent a modifier of susceptibility to cancer. PMID: 26315998
LOC389641 promotes pancreatic ductal adenocarcinoma progression and increases cell invasion by regulating E-cadherin with the possible involvement of TNFRSF10A. PMID: 26708505
Results showed DR4 promotor methylation and low protein expression level in patients with lung squamous carcinoma which correlated with the prognosis of the disease. PMID: 26238205
Genetic variation of TRAIL-R1 rs4242392 is linked with response to interferon-based therapy for hepatitis C virus infection, and genetic variation IFN-gamma rs2069707 is associated with natural clearance of hepatitis C virus infection. PMID: 25798684
The rs13278062 polymorphism of the DR4 gene not only can confer an increased risk for crohn disease, but may also influence the location of the lesions and the disease behaviors. PMID: 26418999
Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells. PMID: 25605010
Our observations suggested that genetic variants of the DR4 gene significantly influence the risk of PCa in North Indian population and might be involved in the etiology of PCa. PMID: 25691252
TRAIL-DR4 polymorphism is associated with laryngeal squamous cell carcinoma. PMID: 25605161
was statistically significant association between DR4 expression in basal cell carcinoma and histopathologic subtypes PMID: 24212133
Over-expression of TRAIL-R1 is associated with breast cancer. PMID: 25230899
human TRAIL-R1 SNPs modulate the innate immune response against chlamydial infection. This is the first evidence that human TRAIL-R1 is a negative regulator of inflammation and plays a role in modulating Chlamydia pathogenesis. PMID: 24695582
DR4 polymorphism C626G and A683 rather than A1322G are associated with cancer risk. PMID: 24761920
DR4 haplotypes are associated with increased susceptibility of gallbladder carcinoma in north Indian population. PMID: 24587306
Report DR4 up-regulation in alveolar epithelial cells from idiopathic pulmonary fibrosis patients. PMID: 24551275
propose a model of TRAIL receptor interference driven by PLAD-mediated formation of receptor heterodimers on the cell membrane PMID: 24764293
Investigated the association between G422A, C626G, A683C and A1322G polymorphisms in DR4 gene and lung cancer. PMID: 23661154
C626G and A1322G polymorphisms of DR4 are associated with increased cancer risk, but the A683C polymorphism is rarely associated with cancer risk PMID: 24492941
Malignant transformation in the endometrium is related to reduction of membrane DR4 and DR5 expression PMID: 23815209
the gradual increase in TRAIL receptor expression during colorectal carcinogenesis is at least partially mediated through increased beta-catenin expression. PMID: 24379239
lipid microdomains could exert a catalytic role for DR4-mediated cell death. PMID: 24136227
SNP rs13278062, but not rs1713985 showed nominal evidence of association with AMD in a total of 1273 cases and 1652 controls of Chinese descent. PMID: 24235014
The antiproliferative GSI-I/TRAIL synergism was stronger in ER-negative MDA-MB-231 breast cancer cells compared with ER-positive MCF-7 cells. In MDA-MB-231 cells, GSI-I treatment induced upregulation of DR4 and DR5 TRAIL receptors PMID: 23686163
Deletion of TRAIL-R2) is relevant to the loss of 8p21.3 and plays a role in the pathogenesis of multiple myeloma. PMID: 23423784
Loss of membrane TRAIL-R1 expression is associated with early stage colorectal cancer. PMID: 23284732
endogenous MARCH-8 regulates the steady-state cell surface expression of TRAIL-R1. PMID: 23300075
the C626G polymorphism of DR4 may be associated with the risk and severity of lumbar disc degeneration in the Chinese Han population PMID: 23050498
Endometriosis is not associated with osteoprotegerin gene polymorphism. PMID: 22392486
DR4 is forming DISC complex to activate proximal caspases for apoptosis by TRAIL. PMID: 22240897
we found that the TRAIL receptor I wild type with threonine at amino acid position 209 (626C) and alanine at position 228 (638A) is associated with an increased risk of Hepatocellular carcinoma in patients with chronic hepatitis C. PMID: 22401174
DR4, both as the complete form or as its new short isoform, is involved in TRAIL sensitivity in Ewing's sarcoma. PMID: 22258765
A significant association of DR4 683A > C with a higher risk for ovarian cancer in carriers of BRCA1 mutations. PMID: 21484799
The key differential events in apoptotic cells are p53-dependent activation of the DR4 death receptor pathway, caspase 8-mediated cleavage of BID, and BID-dependent activation of poised BAX at the mitochondria. PMID: 22246181
miR-25 target DR4 provides a mechanism by which miR-25 contributes to evasion of TRAIL-induced cholangiocarcinoma apoptosis PMID: 21953056
This pilot study suggests that loss of TRAIL receptors is a frequent feature of hepatocellular carcinoma and an independent predictor of survival in patients undergoing partial hepatectomy. PMID: 20889918
ATRA upregulated TRAIL-R1 transcription in human cancer cells via 2 putative retinoic acid response elements: Pal-17 (a palindrome separated by 17 bases) & DR-11 (a direct repeat separated by 11 bases) in the 5'-flanking region. PMID: 21685476
Association of death receptor 4, Caspase 3 and 5 gene polymorphism with increased risk to bladder cancer in North Indians. PMID: 21700414
There was no chenage in expression of DR4 in leukemic cell lines after treatment with sodium butyrate. PMID: 19379558
The rs4242392 SNP of the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 gene predicted poor interferon-based HCV treatment response in HIV/HCV-coinfected patients. PMID: 20802294
Data show that the apoptosis mechanisms underlying this sensitization mainly involved diosgenin-induced p38 MAPK pathway activation and subsequent DR5 overexpression. PMID: 21195543
TRAIL-R1 expression was an independent prognostic marker for better survival in all CRC samples and even in the CRC group that received adjuvant therapy PMID: 20673328
TRAIL receptor DR4 was highly expressed in THP-1 & LPS-primed primary monocytes but not in the non-primed primary monocytes. TRAIL induces monocyte migration mediated by TRAIL receptor DR4 via the RhoGTPase signaling pathway. PMID: 20638129
five tentative epitopes on human TRAIL-R1 were shown to be post-translationally modified on some tumor cell lines. PMID: 20363213
Human DR4 is regulated by activator protein 1 via the AP-1-binding site at -350/-344. PMID: 12082627
induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway PMID: 12239152
Tyrosine-based sorting signal in adenovirus RID plays a role in RID's ability to down-regulate TRAIL R1 receptor and inhibit TRAIL induced apoptosis PMID: 12388693
Decreased expression of DR4 may contribute to prolonged survival of eosinophils in the airways of allergic asthmatics following segmental antigen challenge. PMID: 12421985

Hide All

Subcellular Location

Cell membrane; Single-pass type I membrane protein. Membrane raft. Cytoplasm, cytosol.

Tissue Specificity

Widely expressed. High levels are found in spleen, peripheral blood leukocytes, small intestine and thymus, but also in K-562 erythroleukemia cells, MCF-7 breast carcinoma cells and activated T-cells.

Database Links

HGNC: 11904

OMIM: 603611

KEGG: hsa:8797

STRING: 9606.ENSP00000221132

UniGene: Hs.213467

Code	CSB-MP023964HU1
Abbreviation	Recombinant Human TNFRSF10A protein, partial (Active)
MSDS	MSDS Datasheet
Size	$102
	Order now
Image	(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel. Activity Measured by its binding ability in a functional ELISA.Immobilized Human TNFRSF10A at 2 μg/ml can bind anti-TNFRSF10A recombinant antibody(CSB-RA023964MA1HU).The EC₅₀ is 1.038-1.260 ng/mL. Biological Activity Assay Activity TNFRSF10A Recombinant Monoclonal Antibody(CSB-RA023964MA1HU) captured on Protein A Chip can bind Human TNFRSF10A with an affinity constant of 0.851 nM as detected by MetaSPR Assay (WeSPRTM 200). Biological Activity Assay The purity of TNFRSF10A was greater than 95% as determined by SEC-HPLC
Have Questions?	Leave a Message or Start an on-line Chat

Recombinant Human Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A), partial (Active)

Product Details

Related Products

Customer Reviews and Q&A

Target Background

×CloseMessage